<DOC>
	<DOCNO>NCT00138970</DOCNO>
	<brief_summary>To compare renal function ( 51Cr-EDTA clearance ) 12 month posttransplant , primary renal allograft recipient ( cadaveric donor ) low immunogenic risk , 0 DR mis-match , receive immunosuppressive therapy A ) Zenapax® ( 5 dos ) , CellCept® ( 1.5 g bid. , aim TDM total trough concentration 2-6 mg/L ) prednisolone B ) Sandimmun Neoral® ( full dose ) , CellCept® ( 1.0 g bid . ) prednisolone .</brief_summary>
	<brief_title>Calcineurin Inhibitor-Free Immunosuppression Renal Transplant Recipients Low Immunogenic Risk</brief_title>
	<detailed_description>Primary Objective To compare renal function ( 51Cr-EDTA clearance ) 12 month posttransplant , primary renal allograft recipient ( cadaveric donor ) low immunogenic risk , 0 DR mis-match , receive immunosuppressive therapy A ) Zenapax® ( 5 dos ) , CellCept® ( 1.5 g bid. , aim TDM total trough concentration 2-6 mg/L ) prednisolone B ) Sandimmun Neoral® ( full dose ) , CellCept® ( 1.0 g bid . ) prednisolone . Secondary Objectives To compare two treatment group regard : patient graft survival ( 12 month ) , biopsy-proven presumptive rejection episode ( 3 12 month ) , posttransplant ( 12 month ) incidence severity hypertension , hyperlipidemia , glucose intolerance , incidence infection tolerability “ success rate ” TDM guide CellCept® dose calcineurin inhibitor-free immunosuppressive protocol 12 month .</detailed_description>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Patients either gender 18 year age . 2 . Patients recipient primary , 0 DR mismatch renal allograft cadaveric donor ( age 10 70 year ) . 3 . Patients single organ recipient ( kidney ) . 4 . If patient woman childbearing potential , must use safe contraceptive . 5 . Patients previously treat Zenapax® Simulect® . 6 . Patients must capable understand information give study , include purpose risk , must sign statement inform consent accordance Helsinki declaration . 7 . Patients white blood count great 2.5 x 109 /L ( IU ) , platelet count great 100 x 109 /L ( IU ) haemoglobin great 6 g/dL time entry study . 1 . Patients recipients HLAidentical renal transplant . 2 . PRA positive ( &gt; 20 % ) patient time alst 6 month . 3 . Patients unable stay outside hospital outpatient 3 month . 4 . Patients unable receive oral medication . 5 . Patients active peptic ulcer disease . 6 . Patients active infection . 7 . Patients disorder might interfere ability absorb oral medication , severe diarrhoea patient previously diagnose diabetic gastroenteropathy . 8 . Patients pregnant nursing mother . 9 . Patients ongoing malignancy , exclude adequately treat skin carcinoma . 10 . Patients able adhere investigational immunosuppressive therapy . 11 . Patients receive bileacid sequestants .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Cadaveric donor</keyword>
	<keyword>Calcineurine free</keyword>
</DOC>